Breast Cancer Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Anthracyclines, Antimetabolites, Epothilones, Taxanes, Alkylating Agents, Hormonal Therapy, Aromatase Inhibitors, Selective Oestrogen-Receptor Modulators), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region Forecast 2019-2030    

Breast Cancer Treatment Market size was valued at US$ 33.20 billion in 2023, and is poised to grow at a CAGR of 7.9% from 2024-2030. Breast cancer is the disease occurs when uncontrolled growth of malignant cells in the breast tissue that is most commonly occurs in female than men. Treatment of breast cancer depends on various factors such as the type of breast cancer, the size of a tumour, stage of breast cancer and the grade of cancer cells. The breast cancer can be treated by various therapies such as radiation therapy, chemotherapy, hormone therapy, targeted therapy and bone-directed therapy.

The common signs and symptoms associated with breast cancer include change in the breast shape, forming of lumps in the breast, dimpling of skin, and red scaly patches on the skin. In severe conditions, bone pain, swelling of lymph nodes, problems in respiration, and yellow skin may appear. The breast cancer commonly occurs due to drinking alcohol, being female, obesity, ionizing radiation, family history and older age among others. Breast cancer is diagnosed by taking a biopsy of lump. After the diagnosis, further tests are carried to determine the cancer stage and suitable treatment for the disease.

Key Developments

• In July 2017, U.S. FDA Approved Puma Biotechnology's Nerlynx (Neratinib) for the treatment of HER2-positive breast cancer in early stag. In July 2017, AstraZeneca received the approval from European Commission (EC) for  Faslodex (fulvestrant) for the breast cancer treatment.